StockGlow

Fennec Pharmaceuticals Inc. (FENC)

Sells a drug that protects children's hearing during cancer chemotherapy

$9.94-0.03%Healthcare
Compare FENC with
StockGlow Score
89
Bullish
BearishBullish
1 year ago+26.8%

The outlook

FENC is trading above both its 50- and 200-day moving averages, positioned roughly three-quarters of the way up its 52-week range. Analysts' average price target sits about 58% above the current price. The overall data picture leans bullish based on current positioning and valuation metrics.

What’s behind the score

Price trendAbove its 50- & 200-day averages
52-week range76% of the way from its 52-week low to high
Price targetAvg target +58% vs current price

Analyst price target

~12-month · 6 analysts
$15.67average target+57.6% vs now
Now $9.94
Low $13.00High $18.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$345.3M
52-wk high
$11.31
52-wk low
$5.65
50-day avg
$9.92
200-day avg
$8.21
Trailing P/E
—

Similar stocks

ETONEton Pharmaceuticals, Inc.$46.66+10.28%VRCAVerrica Pharmaceuticals Inc.$5.40+2.08%CSBRChampions Oncology, Inc.$5.53-8.75%FULCFulcrum Therapeutics, Inc.$3.72-0.27%MGTXMeiraGTx Holdings plc$11.82-3.90%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy